UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/569,024	09/07/2006	Edwin Lowe	DAIRY88.018APC	9116
	7590 04/03/200 RTENS OLSON & BE		EXAMINER	
2040 MAIN STREET			WONG, LESLIE A	
FOURTEENTH FLOOR IRVINE, CA 92614			ART UNIT	PAPER NUMBER
			1794	
			NOTIFICATION DATE	DELIVERY MODE
			04/03/2009	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jcartee@kmob.com eOAPilot@kmob.com

	Application No.	Applicant(s)				
Office Action Occurrence	10/569,024	LOWE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Leslie Wong	1794				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence add	dress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
	-· action is non-final.					
3) Since this application is in condition for allowan		secution as to the	merits is			
closed in accordance with the practice under <i>E</i>						
		0.0.2.2.0.				
Disposition of Claims						
<ul> <li>4) Claim(s) 1-8 and 10-18 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> <li>5) Claim(s) is/are allowed.</li> <li>6) Claim(s) 1-8 and 10-18 is/are rejected.</li> <li>7) Claim(s) is/are objected to.</li> <li>Claim(s) are subject to restriction and/or election requirement.</li> </ul>						
Application Papers						
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the confidence of Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examiner	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CF				
Priority under 35 U.S.C. § 119						
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of:  1. ☐ Certified copies of the priority documents 2. ☐ Certified copies of the priority documents 3. ☐ Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received i (PCT Rule 17.2(a)).	on No  In this National S	Stage			
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 2/17/06.	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal Pa 6)  Other:	te				

Application/Control Number: 10/569,024

Art Unit: 1794

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-7, 10-13, and 15-17 are rejected under 35 U.S.C. 102(b) as being anticipated by Bisson et al (US 5714182).

Bisson et al teach a process for preparing a yoghurt comprising the following steps: a) adding whey protein to a milk-based raw material to have a casein:whey protein ratio of from 70:30 to 40:60; b) adjusting to a pH of from 6.1 to 6.7; c) heating the milk to a temperature of from 70°C to 95°C for a time of 1 minute to 15 minutes; and d) acidifying using a microorganism treatment or chemical acidification to prepare a yoghurt (see entire patent, especially the abstract and claims 1 and 4).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-8 and 10-118 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bisson et al (US 5714182) in view of Takenawa et al (US 4842873 and 4988519) and Ohara et al (US 6313319).

Bisson et al is cited as above.

The claims differ as to the use of glucono-delta-lactone.

Art Unit: 1794

Takenawa et al (US 4842873 and 4988519) disclose the conventional use of glucono-delta-lactone as a coagulant (see claim 1 for each patent).

Ohara et al disclose the conventional use of glucono-delta-lactone as a coagulant (see Brief Summary).

It would have been obvious to a person of ordinary skill in the art, at the time the invention was made, to use glucono-delta-lactone as taught by Takenawa et al (US 4842873 and 4988519) and Ohara et al in that of Bisson et al because the use of glucono-delta-lactone is conventional in the art. The glucono-delta-lactone is used for its art-recognized function to obtain no more than expected results.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leslie Wong whose telephone number is (571)272-1411. The examiner can normally be reached on Tuesday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Keith Hendricks can be reached on 571-272-1401. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/569,024 Page 4

Art Unit: 1794

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Leslie Wong/ Primary Examiner, Art Unit 1794

LAW March 27, 2009